Preserve the potency of Therapeutic Peptides throughout the entire drug discovery workflow

SOUTHWARK, U.K. - June 5, 2015 - PRLog -- The degree of variation by which peptides will adhere to plasticware can confuse results and cause inaccuracies in potency predictions. Evaluation of acoustic non-contact methods for peptide serial dilution compared with traditional tip-based methods, has shown that the former better preserves the potency curves for glucagon-like peptide-1 and glucagon peptide analogues throughout the entire drug delivery workflow.
(Source: ‘Acoustic Dispensing Preserves the Potency of Therapeutic Peptides throughout the Entire Drug Discovery Workflow’, 22 May 2015, PubFacts)

Against this backdrop, SMi’s 2nd annual Peptides conference, taking place on the 8th and 9th July 2015 in London, will address these latest developments by providing valuable insight on innovative topics such as cyclic peptides, R&D platforms, manufacture and stability, oral delivery of peptides, cell permeable peptide therapeutics for cancer treatments and development of peptides for the clinic.

Speaker Panel includes:
• Lutz Jermutus, Senior Director, R&D & Product Development Team Leader, MedImmune
• Jörg Vollmer, CEO, Nexigen
• Stephen Hale, SVP Biological Sciences, Ensemble Therapeutics
• Dan Teufel, Head of Chemistry, Bicycle Therapeutics
• Juan J. Diaz-Mochon, Group Leader NANOCHEMBIO Research Team, GENYO
• Renata Zbozien, Research Manager, Haemostatix

To view the full speaker line-up and two-day conference programme, visit http://www.smi-online.co.uk/2015peptides33.asp